Search for a trial

Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)

To determine whether aleglitazar reduces cardiovasculair mortality and morbidity (defined as non-fatal myocardial infarction (MI) and non-fatal stroke) in patients with a recent ACS event and type 2 diabetes.

Acute and chronic administration of the folate derivate levofolinate to patients with acute myocardial infarction: A double-blinded placebo-controlled pilot study.
"Folate in Acute Myocardial Infarction (FolAMI-study)"

A controlled trial to investigate whether by reducing eNOS uncoupling, by direct super oxide scavenging and by up regulating the high-energy phosphate pool, a high dose of intravenous levofolinate can reduce ischemia- and reperfusion-induced…

The effect of rosiglitazone on ischemia-reperfusion-injury using annexin A5 scintigraphy.
A double blind placebo- controlled cross-over study in subjects with the metabolic syndrome

To estimate the effect of rosiglitazone compared to placebo on ischemia-reperfusion injury as assessed by annexin A5 scintigraphy in the human forearm in subjects with the metabolic syndrome.

A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-groupStudy to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Moderate Renal Impairment and Acute Myocardial Infarction

The primary objective of this study is to assess the renal safety of CSL112 in subjects with moderate RI and AMI after administration of up to 4 weekly infusions of CSL112.The secondary objectives of the study are:1. To further characterize the…